Hybrid immunity and strategies for COVID-19 vaccination

Hui, David

doi:10.1016/s1473-3099(22)00640-5

Cited by 29 publications

(18 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While original mRNA anti-SARS-CoV-2 vaccines are less effective in the prevention of infection by the Omicron (42), a booster vaccination may reduce severe outcomes, including hospital admission in the general population (43) as well as immunocompromised (44) and other vulnerable populations (45). New generations of multivalent mRNA vaccines could provide better efficiency against novel variants along with an acceptable safety profile (46) vaccination and infection frequencies also raise the question of hybrid immunity, which may be another critical factor in reducing infection risk (47). Further investigation is needed.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

SARS-CoV-2-specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressiva patients

et al. 2022

View full text Add to dashboard Cite

IntroductionFibrodysplasia ossificans progressiva (FOP) is characterized by progressive heterotopic ossification triggered by various conditions, such as trauma, infection, including COVID-19 infection, and vaccination. Although SARS-CoV-2 vaccinations prevent poor outcomes in the general population, there is limited evidence on safety, immunogenicity, and efficacy of SARS-CoV-2 vaccines for inpatients with FOP.MethodsA case series of two patients with FOP focused on humoral, cellular post-vaccination response, and the incidence of adverse events after administration of the BNT162b2 vaccine (Comirnaty).ResultsInjection site reactions, fever, myalgia, and fatigue were the most common adverse events (AE). Neither severe AE (SAE), nor disease flare-ups were observed. No differences between patients with FOP and healthy controls were observed in humoral and cellular responses.ConclusionsThe BNT162b2 vaccine induced high humoral and cellular response levels in patients with FOP. Vaccination was not associated with SAE or disease relapse. The AEs spectrum was comparable to that of the general population.

show abstract

Section: Discussionmentioning

confidence: 99%

“…New generations of multivalent mRNA vaccines could provide better efficiency against novel variants along with an acceptable safety profile ( 46 ). High vaccination and infection frequencies also raise the question of hybrid immunity, which may be another critical factor in reducing infection risk ( 47 ). Further investigation is needed.…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2-specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressiva patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Also, people infected with BA.1 variant reduced the risk of re-infection with BA.2 cariant by 72%, and its immunity level was 38% higher than the pre-Omicron SARS-CoV-2 strain. The combination of three doses (BA.2.12.1, BA.4, and BA.5) of vaccine and previous immunity with BA.1 variant was led to increase of immunity up to 95% for 5 months [20] …”

Section: The Covid-19 Vaccine Development Landscapementioning

confidence: 98%

An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations

Mirtaleb

Falak

Heshmatnia

et al. 2023

International Immunopharmacology

View full text Add to dashboard Cite

“…For the estimation of VE at the population level, the modeling of the individual hybrid immunity is one of the key factors in forecasting the number of newly positive cases [ 17 ] where a high percentage of people are both vaccinated and primarily infected. This estimation is also useful for developing vaccine strategies [ 18 ]. Questions that remain are (1) to what degree have people obtained hybrid immunity, and (2) how does it affect the DPC in the real world.…”

Section: Introductionmentioning

confidence: 99%

Projection of COVID-19 Positive Cases Considering Hybrid Immunity: Case Study in Tokyo

et al. 2023

View full text Add to dashboard Cite

Since the emergence of COVID-19, the forecasting of new daily positive cases and deaths has been one of the essential elements in policy setting and medical resource management worldwide. An essential factor in forecasting is the modeling of susceptible populations and vaccination effectiveness (VE) at the population level. Owing to the widespread viral transmission and wide vaccination campaign coverage, it becomes challenging to model the VE in an efficient and realistic manner, while also including hybrid immunity which is acquired through full vaccination combined with infection. Here, the VE model of hybrid immunity was developed based on an in vitro study and publicly available data. Computational replication of daily positive cases demonstrates a high consistency between the replicated and observed values when considering the effect of hybrid immunity. The estimated positive cases were relatively larger than the observed value without considering hybrid immunity. Replication of the daily positive cases and its comparison would provide useful information of immunity at the population level and thus serve as useful guidance for nationwide policy setting and vaccination strategies.

show abstract

Hybrid immunity and strategies for COVID-19 vaccination

Cited by 29 publications

References 7 publications

SARS-CoV-2-specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressiva patients

SARS-CoV-2-specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressiva patients

An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations

Projection of COVID-19 Positive Cases Considering Hybrid Immunity: Case Study in Tokyo

Contact Info

Product

Resources

About